Adamas Pharmaceuticals, Inc.: Series D $40M

Posted in I - Series D, Q - 3Q09, R - WEST, X - Antiinfective, X - CNS, X - Dementia, X - Influenza, X - Parkinson's, XX - CA

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Curemark, Inc.: Series A $6.5M

Posted in I - Series A, Q - 3Q09, R - NORTH EAST, X - ADHD, X - CNS, XX - NY

Curemark (Rye, NY) a clinical-stage biopharma company focused on the treatment of neurological disease (autism and ADHD), clased a $6.5M Series A financing. Participants were not disclosed.

Helicon Therapeutics, Inc.: Series F $50M

Posted in I - Series F, Q - 3Q09, R - WEST, X - Alzheimer's, X - CNS, XX - CA

Helicon Therapeutics (San Diego, CA) a clinical-stage biotech focused on the development of modulating memory formation from short-term memories, and the conversion of short-term memory to long-term memory, closed a $50M Series F financing. Participants in the round were not named

CeNeRx BioPharma, Inc.: Series C $4M

Posted in I - Series C, Q - 2Q09, R - SOUTH EAST, X - CNS, XX - NC

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.

Marinus Pharmaceuticals, Inc.: Series B $20M

Posted in I - Series B, Q - 2Q09, R - NORTH EAST, X - CNS, X - Depression, X - PTSD, X - Seizures, XX - CT

Marinus Pharmaceuticals (Branford, CT) a clinical-stage company focused on reformulation and development of therapeutics for the treatment of CNS, psychiatric and pain disorders, closed a $20M Series B financing. Participants include Canaan Partners, Domain Associates, Sofinnova Ventures and Foundation Medical Partners.

KeyNeurotek Pharmaceuticals, AG: Series C $10.9M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Autoimmune, X - CNS, X - Incontinence, X - Stroke

KeyNeurotek Pharmaceuticals (Germany) a clinical-stage small molecule company focused on autoimmune and CNS diseases, closed a $10.9M Series C financing. Participants include DVC Deutsche Venture Capital, IBG Beteiligungsgesellschaft and KfW Bankengruppe.

Mithridion, Inc.: Series B $2.9M

Posted in I - Series B, Q - 1Q09, R - MID WEST, X - Alzheimer's, X - CNS, XX - WI

Mithridion (Madison, WI) an early-stage drug development company focused on central nervous system disorders, including Alzheimer’s disease, closed a $2.9M Series B financing. Participants include Venture Investors, Rocket Ventures, The State of Wisconsin Investment Board and Wisconsin Investment Partners.

Psyadon Pharmaceuticals, Inc.: Series A $8M

Posted in I - Series A, Q - 4Q08, R - MID ATLANTIC, X - CNS

Psyadon Pharmaceuticals (Germantown, MD) early-stage developer of glutamate transport modulation for CNS indications, closed a $8M Series A financing. Participants include New Enterprise Associates, Aberdare Ventures and Domain Associates.

Knopp Neurosciences, Inc.: Series B $27M

Posted in I - Series B, Q - 4Q08, R - NORTH EAST, X - ALS, X - CNS

Knopp Neurosciences (Pittsburgh, PA) early-stage drug discovery and development company focused on amyotrophic lateral sclerosis and other neurological disorders, closed a $27M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

BrainsGate, Ltd.: Series C $27.5

Posted in I - Series C, Q - 3Q08, R - INTERNATIONAL, X - CNS

BrainsGate (Israel) development-stage company focused on electrical stimulation for CNS disorders, closed a $27.5M Series C financing. Participants include Johnson & Johnson Development Corp., Agate Medical Investments, Elron Electronic Industries, Pitango Venture Capital, MB Venture Capital and Alice Lab.

« Previous Entries

to top of page...